Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.41 |
| ▸ | SHBG | P04278 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 2/20 | 0.33 |
| ▸ | SNCA | P37840 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267390 | 1.00 | NR3C1 (0.41) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL1880354 | 1.00 | NR3C1 (0.41) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL17547203 | 0.97 | NR3C1 (0.39) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL2631223 | 0.90 | NR3C1 (0.40) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL16842370 | 0.90 | NR3C1 (0.40) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL2618325 | 0.90 | NR3C1 (0.40) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL13476641 | 0.78 | NR3C1 (0.47) | NR3C1SHBGHSD17B10ARPGR | |
| SCHEMBL13476643 | 0.73 | NR3C1 (0.41) | NR3C1 | |
| SCHEMBL1876528 | 0.73 | NR3C1 (0.41) | NR3C1 | |
| SCHEMBL12654408 | 0.70 | NR3C1 (0.40) | NR3C1ARCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | BANK OF AMERICA, N.A. | 2019-11-14 | — | — | US | disclosed |
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160264968-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9394540-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20080076795-A1 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-7282591-B2 | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282591-B2 | 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators | MERCK & CO., INC. (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | MASSACHUSETTS, UNIVERSITY OF | 2007-05-10 | — | — | US | disclosed |
| WO-2007022506-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022470-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-4077996-A | Process for the preparation of trans-deca hydronaphthalene derivatives | SCHERING AKTIENGESELLSCHAFT (DT) | 1978-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | NR3C1 3599/4885SHBG 4866/4885HSD17B10 3244/4885 |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | NR3C1 1492/4885SHBG 1109/4885HSD17B10 2639/4885 |
| US-20080076795-A1 | 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | NR3C1, NR3C2, GRK5 | NR3C1 1/4885SHBG 125/4885HSD17B10 1165/4885 |
| US-20190345498-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | NR3C1 1492/4885SHBG 1109/4885HSD17B10 2639/4885 |
| US-20070105803-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | NR3C1 3599/4885SHBG 4866/4885HSD17B10 3244/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | NR3C1 1492/4885SHBG 1109/4885HSD17B10 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.